ArticleWorld journal of urology2017
Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer.
Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.European urology · 2026Review
- Epithelial to mesenchymal transition and M2 macrophages drive aggressiveness in murine and human sarcomatoid urothelial carcinoma.bioRxiv : the preprint server for biology · 2026Article
- [Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology].Urologie (Heidelberg, Germany) · 2026Review
- A case series: Four cases of urothelial carcinoma with sarcomatoid differentiation.Frontiers in oncology · 2026Article
- Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.European urology · 2025Article
- Clinicopathological features and treatment outcomes of urothelial carcinoma variant histologies and non-urothelial bladder cancers.International urology and nephrology · 2025Article
- Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development.Biomedicines · 2025Review
- [Analysis of Clinicopathological Characteristics and Factors Affecting the Prognosis of Patients With Resectable Sarcomatoid Carcinoma of the Bladder].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- CT and MRI features of sarcomatoid urothelial carcinoma of the bladder and its differential diagnosis with conventional urothelial carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Clinical efficacy analysis of partial cystectomy and radical cystectomy in the treatment of muscle-invasive sarcomatoid carcinoma of the urinary bladder.Frontiers in oncology · 2024Article
- Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis.Bladder cancer (Amsterdam, Netherlands) · 2024Article
- Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.Clinical genitourinary cancer · 2023Article
- The Many Faces of Urothelial Carcinomas: An Update From Pathology to Clinical Approach and Challenges in Practice.Urology research & practice · 2023Article
- Prognostic value of the sarcomatoid component in bladder cancer: A propensity score matching study.Oncology letters · 2023Article
- The effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Sarcomatoid variant of urothelial carcinoma of renal pelvis with direct invasion of the pancreas and descending colon.IJU case reports · 2022Article
- Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients.Central European journal of urology · 2022Article
- Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent.World journal of urology · 2021Article
- Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes.Cancer cell international · 2020Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo characterize the treatment patterns and survival outcomes of sarcomatoid bladder cancer, a rare urothelial variant histology using a large population level cancer database.
methodsThe National Cancer Database was queried for all cases of sarcomatoid bladder cancer using International Classification of Disease-O-3 morphologic code 8122 between 2004 and 2014. Primary outcome was overall survival.
resultsA total of 489 patients met our inclusion criteria and were included in our analysis. Average age at diagnosis was 70.4 years. The majority of the population was male (61.8%) and Caucasian (92.2%). Tumor characteristics included 23.7% cT1, 41.1% cT2 and 15.3% cT3 or above. Median overall survival was 18.4 months (95% CI 13.3-23.6). On multivariate Cox proportional analysis, radical cystectomy alone or with multimodal therapy (chemotherapy or radiotherapy) resulted in a statistically significant reduction in the risk of death as compared to bladder preservation surgery alone. Survival in the radical cystectomy group did not differ between radical cystectomy alone and those receiving either neoadjuvant or adjuvant chemotherapy.
conclusionsSarcomatoid bladder cancer has poor prognosis with 18.4-month median overall survival. While our data suggest that aggressive treatment improves outcomes, the role of multimodal therapy is unclear. Future study should continue to focus on multi-institutional collaboration to determine the most effective therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.